« Previous Next » Contraception
Volume 80, Issue 5 , Pages 430-435 , November 2009

Extended regimens of the vaginal contraceptive ring: cycle control

Cristina Aparecida Falbo Guazzelli
- Family Planning Clinic, Department of Obstetrics and Gynecology of Sao Paulo Federal University (UNIFESP), Bairro Jardim, São Paulo, CEP 09090-050, Brazil
- Corresponding author. Tel.: +55 11 55722605; fax: +55 11 55722605.
Fernando Augusto Barreiros
- Family Planning Clinic, Department of Obstetrics and Gynecology of Sao Paulo Federal University (UNIFESP), Bairro Jardim, São Paulo, CEP 09090-050, Brazil
- Western Paulista University, Presidente Prudente, São Paulo, 19015041, Brazil
Ricardo Barbosa
- Western Paulista University, Presidente Prudente, São Paulo, 19015041, Brazil
Fábio Fernando de Araújo
- Family Planning Clinic, Department of Obstetrics and Gynecology of Sao Paulo Federal University (UNIFESP), Bairro Jardim, São Paulo, CEP 09090-050, Brazil
Antonio Fernandes Moron
- Family Planning Clinic, Department of Obstetrics and Gynecology of Sao Paulo Federal University (UNIFESP), Bairro Jardim, São Paulo, CEP 09090-050, Brazil

Received 2 July 2008 ,Revised 8 May 2009 ,Accepted 9 May 2009.

References

Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142–1149
FDA approves NuvaRing contraceptive implant. J Gend Specif Med. 2002;5:6
- MEDLINE
Roumen F, Apter D, Mulders T, Dieben T. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001;16:469–475
- MEDLINE
- CrossRef
Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002;100:585–593
- MEDLINE
- CrossRef
Roumen F. Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing. Eur J Contracept Reprod Health Care. 2002;(Suppl 2):19–24
Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with a an oral contraceptive containing 30 mcg ehtinylestradiol and 150 mcg levonorgestrel: a randomized trial. Hum Reprod. 2005;20:557–562
- MEDLINE
- CrossRef
Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a lowdose oral contraceptive: a randomized trial. Contraception. 2003;67:9–13
Edelman A. Menstrual nirvana: amenorrhea through the use of continuous oral contraceptives. Curr Womens Health Rep. 2002;(6):434–438
Vree M. Lower hormone dosage with improved cycle control. Eur J Contracept Reprod Health Care. 2002;(Suppl 2):25–30
Miller L, Verhoeven C, Hout J. Extended regimens of the contraceptive vaginal ring. Obstet Gynecol. 2005;3:473–482
World Health Organization . Medical eligibility criteria for contraceptive use. Reproductive Health and Research. 3rd ed. Geneva: WHO; 2004;
Mishell D, Guillebaud JM, Westhoff CL, et al. Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception. Contraception. 2006;75:4–10
Mishell DR, Guillebaud J, Westhoff CL, et al. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception. 2007;75(1):11–15
Altman D. In: Practical Statistics for medical research. London: Chapman and Hall; 1991;p. 250
Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:64–72, 93.